ATE401328T1 - Verbrückte n-arylsulfonylpiperidine als gamma- sekretaseinhibitoren - Google Patents

Verbrückte n-arylsulfonylpiperidine als gamma- sekretaseinhibitoren

Info

Publication number
ATE401328T1
ATE401328T1 AT04751862T AT04751862T ATE401328T1 AT E401328 T1 ATE401328 T1 AT E401328T1 AT 04751862 T AT04751862 T AT 04751862T AT 04751862 T AT04751862 T AT 04751862T AT E401328 T1 ATE401328 T1 AT E401328T1
Authority
AT
Austria
Prior art keywords
secretasis
arylsulfonylpiperidines
bridged
gamma
inhibitors
Prior art date
Application number
AT04751862T
Other languages
English (en)
Inventor
Hubert Josien
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE401328T1 publication Critical patent/ATE401328T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
AT04751862T 2003-05-13 2004-05-11 Verbrückte n-arylsulfonylpiperidine als gamma- sekretaseinhibitoren ATE401328T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47014603P 2003-05-13 2003-05-13

Publications (1)

Publication Number Publication Date
ATE401328T1 true ATE401328T1 (de) 2008-08-15

Family

ID=33452372

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04751862T ATE401328T1 (de) 2003-05-13 2004-05-11 Verbrückte n-arylsulfonylpiperidine als gamma- sekretaseinhibitoren

Country Status (14)

Country Link
US (1) US7368457B2 (de)
EP (1) EP1641801B9 (de)
JP (1) JP2007501859A (de)
CN (1) CN1820010A (de)
AR (1) AR044294A1 (de)
AT (1) ATE401328T1 (de)
CA (1) CA2525124A1 (de)
CL (1) CL2004001011A1 (de)
DE (1) DE602004015110D1 (de)
ES (1) ES2308206T3 (de)
MX (1) MXPA05012268A (de)
PE (1) PE20050555A1 (de)
TW (1) TW200510405A (de)
WO (1) WO2004101562A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
ATE461926T1 (de) * 2004-06-30 2010-04-15 Schering Corp Substituierte n-arylsulfonylheterocyclische amine als gamma-sekretase-hemmer
JP2009504773A (ja) * 2005-08-19 2009-02-05 エラン ファーマシューティカルズ，インコーポレイテッド ガンマセクレターゼの架橋ｎ−二環式スルホンアミド阻害剤
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
AR076936A1 (es) * 2009-06-02 2011-07-20 Vitae Pharmaceuticals Inc Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
EP2686313B1 (de) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazolderivate als glutaminylcyclase-hemmer
EP2794565B1 (de) 2011-12-21 2017-07-26 Novira Therapeutics Inc. Hepatitis-b-viruzide
CA2881057C (en) 2012-08-28 2020-10-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
JP6466348B2 (ja) 2013-02-28 2019-02-06 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
HUE040446T2 (hu) 2013-05-17 2019-03-28 Janssen Sciences Ireland Uc Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére
TW202126620A (zh) 2013-05-17 2021-07-16 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
WO2015011281A1 (en) 2013-07-25 2015-01-29 Janssen R&D Ireland Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MX368158B (es) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JP6553059B2 (ja) 2014-02-05 2019-07-31 ノヴィラ・セラピューティクス・インコーポレイテッド Ｈｂｖ感染の治療のための併用療法
PL3102572T3 (pl) 2014-02-06 2019-04-30 Janssen Sciences Ireland Uc Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
WO2015131773A1 (zh) * 2014-03-06 2015-09-11 上海海雁医药科技有限公司 作为食欲素受体拮抗剂的哌啶衍生物
EP3271019A1 (de) 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocan- und azonanderivate und verfahren zur behandlung von hepatitis-b-infektionen
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
AR106192A1 (es) 2015-09-29 2017-12-20 Novira Therapeutics Inc Formas cristalinas de un agente antiviral contra la hepatitis b
WO2017181141A2 (en) 2016-04-15 2017-10-19 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
SG11202007097QA (en) 2018-03-14 2020-08-28 Janssen Sciences Ireland Unlimited Co Capsid assembly modulator dosing regimen
AU2020223865A1 (en) 2019-02-22 2021-07-15 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
BR112021021454A2 (pt) 2019-05-06 2021-12-21 Janssen Sciences Ireland Unlimited Co Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04247081A (ja) * 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類
CN1348442A (zh) 1999-02-26 2002-05-08 默克公司 新的磺胺化合物及其应用
WO2002076440A2 (en) * 2001-03-23 2002-10-03 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates

Also Published As

Publication number Publication date
CA2525124A1 (en) 2004-11-25
EP1641801A2 (de) 2006-04-05
US7368457B2 (en) 2008-05-06
ES2308206T3 (es) 2008-12-01
JP2007501859A (ja) 2007-02-01
EP1641801B9 (de) 2009-02-25
TW200510405A (en) 2005-03-16
CN1820010A (zh) 2006-08-16
PE20050555A1 (es) 2005-07-19
CL2004001011A1 (es) 2005-03-18
MXPA05012268A (es) 2006-02-10
US20040229902A1 (en) 2004-11-18
DE602004015110D1 (de) 2008-08-28
EP1641801B1 (de) 2008-07-16
WO2004101562A3 (en) 2005-02-10
AR044294A1 (es) 2005-09-07
WO2004101562A2 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
DE602004015110D1 (de) Verbrückte n-arylsulfonylpiperidine als gamma-sekretaseinhibitoren
ATE402934T1 (de) Malonamidderivate als gamma-secretaseinhibitoren
ATE437876T1 (de) Hexahydropyridoisochinoline als dpp-iv- inhibitoren
ATE478868T1 (de) Pyrrolodihydroisochinoline als pde10- inhibitoren
DE602004015724D1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE426599T1 (de) Thiazolylpiperidin derivate als mtp inhibitoren
ATE525377T1 (de) Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
DE602004018837D1 (de) Ptidase-iv-inhibitoren
DK1605897T3 (da) Polyethelen-glycol-link-glp-1-forbindelser
ATE443054T1 (de) Cyano-pyrrolidine als dpp-iv inhibitoren
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
DE602004012154D1 (de) Pyridoä2,3-düpyrimidin-2,4-diamine als pde-2-inhibitoren
IS8320A (is) N-staðgengnir pýrasólýl-amidýl-bensimidasólýl
DE60324208D1 (de) Biarylsulfonamide als mmp-inhibitoren
DE602004019555D1 (de) Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone
DE502004006055D1 (de) 6-arylamino-5-cyano-4-pyrimidinone als pde9a-inhibitoren
ATE538787T1 (de) Benzimidazol-derivative als raf-kinase-hemmer
ATE461926T1 (de) Substituierte n-arylsulfonylheterocyclische amine als gamma-sekretase-hemmer
ATE402700T1 (de) Glycinamid-derivate als raf-kinase-hemmer
ATE462692T1 (de) 3-amino-1-arylpropyl-indole als monoamin- wiederaufnahmehemmer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties